My Portfolio

GeneDx Holdings Corp WGS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 4:41 PM EDT

53.05

+0.03 (+0.06%)

Volume

5,918

53.02

-0.11 (-0.21%)

Volume

1,073,563

52 week range

32.21 - 170.87

Open52.74
Day High54.00
Day Low51.00
Prev Close53.13
52 Week High170.87
52 Week High Date12/02/25
52 Week Low32.21
52 Week Low Date05/06/26

Latest On GeneDx Holdings Corp

Rare disease families find roadmap to drug development at bootcampsMay 7, 2026CNBC.com
How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
Monday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Oracle, Roblox, Robinhood February 9, 2026CNBC.com
Friday could be a wild day of trading on Wall Street. Here's whyDecember 18, 2025CNBC.com
How a reluctant CEO conquered imposter syndrome to turn a biotech profitableOctober 14, 2025CNBC.com
GeneDx CEO Katherine Stueland on her unexpected path to CEO successOctober 14, 2025CNBC.com
Katherine StuelandFebruary 24, 2025CNBC.com

Key Stats

Market Cap1.574B
Shares Out29.69M
10 Day Average Volume1.29M
Dividend-
Dividend Yield-
Beta1.97

Latest On GeneDx Holdings Corp

Rare disease families find roadmap to drug development at bootcampsMay 7, 2026CNBC.com
How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
Monday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Oracle, Roblox, Robinhood February 9, 2026CNBC.com
Friday could be a wild day of trading on Wall Street. Here's whyDecember 18, 2025CNBC.com
How a reluctant CEO conquered imposter syndrome to turn a biotech profitableOctober 14, 2025CNBC.com
GeneDx CEO Katherine Stueland on her unexpected path to CEO successOctober 14, 2025CNBC.com
Katherine StuelandFebruary 24, 2025CNBC.com

KEY STATS

Open52.74
Day High54.00
Day Low51.00
Prev Close53.13
52 Week High170.87
52 Week High Date12/02/25
52 Week Low32.21
52 Week Low Date05/06/26
Market Cap1.574B
Shares Out29.69M
10 Day Average Volume1.29M
Dividend-
Dividend Yield-
Beta1.97

RATIOS/PROFITABILITY

EPS (TTM)-2.67
P/E (TTM)-19.87
Fwd P/E (NTM)79.13
EBITDA (TTM)-7.284M
ROE (TTM)-30.42%
Revenue (TTM)442.678M
Gross Margin (TTM)69.56%
Net Margin (TTM)-17.58%
Debt To Equity (MRQ)38.06%

EVENTS

Earnings Date07/27/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Jefferies Sticks to Its Buy Rating for GeneDx Holdings (WGS)May 27, 2026TipRanks
Insiders Are Buying These 3 Stocks, 5/18/26 — Should You Follow?May 18, 2026TipRanks
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Vir Biotechnology (VIR) and Doximity (DOCS)May 14, 2026TipRanks
GeneDx price target lowered to $85 from $153 at Craig-HallumMay 5, 2026TipRanks
GeneDx price target lowered to $55 from $60 at TD CowenMay 5, 2026TipRanks

Profile

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser...

Jason Ryan CPA

Chairman of the Board

Katherine Stueland

Chief Executive Officer, Director

Bryan Dechairo

Chief Operating Officer

Kevin Feeley

Chief Financial Officer

Address

333 Ludlow Street

North Tower, 6Th Floor

Stamford, CT

06902

United States

https://sema4.com/